A novel diagnostic agent to identify patients with tau neurofibrillary tangles (NFTs), including NFTs isolated to the medial temporal lobe Enigma Biomedical USA (EB USA) today announced the U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection, also previously referred to as MK-6240), a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to i

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment Aug. 10, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up t

Aug. 10, 2026 -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in

Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion. Curium has agreed to buy all outstanding Lantheus shares for $102.50 apiece in cash at closing. Shareholders could receive up to another $12 per share through contingent value rights tied to sales milestones for Lantheus’ prostate cancer, neurology and Definity franchises through 2030. The companies expect to close the transaction in the f

Taisho Pharmaceutical secures exclusive rights to clinically develop, register, and commercialize Kaigene's next-generation FcRn inhibitor, KG006, in Japan. Kaigene will receive a $5 million upfront payment and is eligible for up to a combined total of $22 million and ¥57.5 billion JPY (approximately $351 million) in development, regulatory, and sales milestone payments, plus tiered royalties on net sales. The agreement is expected to establish a robust framework for a three-way multi-regional c

Broadens CREATE's delivery toolkit with access to Monash's novel LNP chemistries and next-generation targeting technologies. Enables rapid evaluation of diverse binder formats and cell-targeting strategies, accelerating development across multiple immune cell types and therapeutic programs. July 31, 2026 -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced a strategic research collaboration with Australia's Monash Un

July 31, 2026 -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026 ASCO Annual Meeting, CellOrigin's scientific co-founder's team presented two new studies on solid tumor cell therapy. The first, CAR-Mix™ multicellular synergistic therapy, combines engineered macrophages with polyclonal T cells and has demonstrated synergistic antitumor activity

Japanese company Eisai has entered an exclusive global licensing agreement with CORE Biomedicine for several preclinical oncology programmes. The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates. The licensed assets focus on targeting key molecular drivers implicated in a range of cancers. The portfolio includes multiple programmes covering different targets and biological pathways. CORE Biomedic

Argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value. Approved by both companies’ boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions. The main asset involved is FB102, Forte Biosciences’ first-in-class anti-CD122 antibody, which will be added to argenx’s immunology portfolio. FB102 was evaluated in Phase Ib studies for vitiligo and celiac disease. Th

Close on the heels of a Phase III win in small-cell lung cancer (SCLC), GSK said Tuesday its Hansoh Pharmaceutical-partnered B7-H3-targeting antibody-drug conjugate (ADC) risvutatug rezetecan (ris-rez) secured another late-stage triumph, this time in osteosarcoma. The ARTEMIS-011 trial, in China, enrolled an estimated 117 patients aged 12 years and above with osteosarcoma who had progressed after at least two prior lines of systemic therapy. Participants were randomised to receive ris-rez or a